TPA 023
TPA 023 性质
| 密度 | 1.33±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | 2-8°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 2.08±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChI | 1S/C20H22FN7O/c1-5-27-17(22-12-23-27)11-29-19-14(20(2,3)4)10-16-24-25-18(28(16)26-19)13-8-6-7-9-15(13)21/h6-10,12H,5,11H2,1-4H3 |
| InChIKey | QKIWQBLNTSQOLY-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=CC2=NN=C(C3=CC=CC=C3F)N2N=C1OCC4=NC=NN4CC |
TPA 023 用途与合成方法
Ki: 0.19-0.41 nM (GABAA)
TPA023 displays good receptor occupancy, when administered orally to rats. The dose of TPA023 resulting in 50% occupancy of rat brain GABAA receptors is 0.42 mg/kg, with the corresponding plasma concentration being 25 ng/mL. TPA023 is also efficacious in the mouse pentylenetetrazole-induced seizure model, providing full seizure protection at a dose of 10 mg/kg i.p. (84% occupancy), with the ED 50 of 0.19-0.41 nM, for protection against tonic convulsions (1.4 mg/kg i.p.) corresponding to around 50% occupancy. TPA023 (3 mg/kg p.o. in 0.5% methyl cellulose) shows anxiolytic-like effect on rats. TPA023 (0.7, 2.0, and 5 mg/kg, p.o.) blocks ketamine's cognitive-impairing ability but does not influence the behavioral symptoms of rhesus monkeys.
TPA 023 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-101640 | TPA 023 | 252977-51-8 | 1mg | 830 |
| 2026-09-15 | HY-101640 | TPA 023 | 252977-51-8 | 5mg | 1661 |
